MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study
Status:
Recruiting
Trial end date:
2021-05-10
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety, tolerability, and antitumor activity
of oleclumab (MEDI9447) in combination with or without durvalumab plus chemotherapy in
subjects with metastatic pancreatic cancer.